<DOC>
	<DOCNO>NCT00516646</DOCNO>
	<brief_summary>Several line evidence suggest Advanced Glycation End-products ( AGEs ) play role development progression heart failure . The AGE-crosslink breaker Alagebrium ( ALT-711 ) improve cardiac function symptom experimental small human heart failure study . These result yet confirm randomize control clinical trial .</brief_summary>
	<brief_title>The BENEFICIAL Study : Evaluating Efficacy Safety Alagebrium ( ALT-711 ) Patients With Chronic Heart Failure</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled , parallel design trial enrol 100 patient ( 2x50 ) stable CHF . Patients randomize either 200 mg Alagebrium twice daily placebo period 9 month . Efficacy measurement perform baseline , end study , include aerobic capacity ( VO2max ) exercise testing , echocardiography , Minnesota Living Heart Failure score , AGEs measurement blood skin , NYHA heart failure class , patient 's physician 's global assessment , level NT-pro-BNP . Safety visit perform 3 month interval . In addition , one safety visit perform 2 week randomization visit 1 month last treatment visit . A total 8 visit perform entire study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>NYHA IIIV heart failure Echocardiographic ejection fraction â‰¤ 40 % Duration heart failure &gt; 3 month Stable heart failure medical therapy &gt; 1 month History myocardial infarction previous 6 month History stroke previous 6 month Clinically significant renal , liver , pulmonary , hematological disease Active treat malignancy within 12 month Uncontrolled diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced Glycation End-products ( AGEs )</keyword>
	<keyword>Alegebrium</keyword>
</DOC>